Algeria to India Pharmaceutical Import

The pharmaceutical trade corridor between Algeria and India has experienced modest activity from 2022 to 2026. During this period, India imported a total of $3,000 USD worth of finished pharmaceutical formulations from Algeria, distributed across nine shipments. The average shipment value stood at approximately $298 USD. This limited trade volume indicates a nascent yet potentially growing relationship in the pharmaceutical sector between the two nations.

The primary products imported include Pazopanib, Plasma, Lenalidomide, and Imatinib, with Pazopanib accounting for 86.5% of the total import value. The involvement of five Algerian suppliers and two Indian buyers suggests a developing trade network, albeit on a small scale. The regulatory oversight by India's Central Drugs Standard Control Organisation (CDSCO) and Algeria's National Drug Regulatory Authority (WHO-GMP) underscores the commitment to maintaining quality and safety standards in this trade corridor.

Algeria's contribution to India's pharmaceutical imports remains minimal, with a total import value of $3,000 USD over the past four years. This positions Algeria as a minor player in India's broader pharmaceutical import landscape. The imports predominantly consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicating a focus on ready-to-use products rather than active pharmaceutical ingredients (APIs) or raw materials.

Between 2024 and 2026, there have been no significant policy changes by the CDSCO or notable trade agreements between India and Algeria specifically targeting the pharmaceutical sector. The limited trade volume suggests that the pharmaceutical trade relationship remains underdeveloped, with potential for growth contingent upon strategic initiatives and enhanced bilateral cooperation.

Algerian pharmaceutical companies seeking to export finished formulations to India must navigate the CDSCO registration process to ensure compliance with Indian regulatory standards. The process involves several key steps:

1. Online Registration: Applicants must visit the CDSCO Sugam portal and create an account by providing necessary details such as applicant type, username, password, and contact information.

2. Application Submission: After account activation, applicants submit the required application form, selecting the appropriate registration category and location.

4. Fee Payment: Payment of applicable registration fees is required.

5. Application Review: CDSCO reviews the application and may request additional information or clarification.

6. Approval: Upon satisfactory review, CDSCO grants the registration, allowing the product to be imported and marketed in India.

The entire process is conducted online, facilitating transparency and efficiency. It's crucial for Algerian companies to ensure all documents are accurate and complete to avoid delays. The timeline for approval can vary, but applicants are typically notified of the outcome via email.

India requires that foreign manufacturing sites adhere to stringent Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of imported pharmaceutical products. Algerian manufacturers must obtain GMP certification from recognized authorities, such as the World Health Organization (WHO), to demonstrate compliance with these standards. The CDSCO may conduct inspections of manufacturing facilities to verify adherence to GMP guidelines. Non-compliance can result in delays or rejection of the registration application.

To import pharmaceutical products into India, Algerian companies must provide comprehensive documentation, including:

• Import License (Form 10): Issued by CDSCO, this license authorizes the importation of specific pharmaceutical products.

• Registration Certificate: Confirms that the product has been approved for sale in India.

• No Objection Certificate (NOC): May be required from the manufacturer or regulatory authority in Algeria.

• Test License: Allows for testing of the imported product in India to ensure compliance with local standards.

• Customs Procedures: Proper documentation is essential for customs clearance, including invoices, packing lists, and certificates of origin.

Ensuring all documentation is accurate and complete is vital to facilitate smooth importation and distribution within India.

The pharmaceutical imports from Algeria to India are predominantly focused on specific therapeutic areas, with a significant emphasis on oncology treatments. Pazopanib, a drug used in cancer therapy, constitutes 86.5% of the total import value, highlighting the demand for specialized treatments not readily available in India. Other imported products include Plasma, Lenalidomide, and Imatinib, which are also utilized in cancer treatment regimens. This trend indicates a niche but critical role for Algerian pharmaceutical products in addressing specific medical needs within India.

Algerian pharmaceutical exports to India include innovator drugs and novel formulations, particularly in the oncology sector. The importation of specialized treatments like Pazopanib and Lenalidomide suggests that these products offer therapeutic benefits not readily available from domestic manufacturers. This underscores the importance of international collaborations in providing advanced medical solutions to meet India's diverse healthcare requirements.

The demand for pharmaceutical imports from Algeria to India is driven by several factors:

• Patent Protection: Imported drugs may be under patent protection in India, limiting domestic production and creating a market for imports.

• Technology Gaps: Algerian manufacturers may possess advanced technologies or formulations not yet developed by Indian companies.

• Quality Requirements: Imported products may meet specific quality standards or certifications that are highly valued in the Indian market.

• Disease Burden: The prevalence of certain diseases in India may necessitate the importation of specialized treatments not available domestically.

These factors collectively contribute to the sustained demand for Algerian pharmaceutical products in India.

India's import tariff structure for pharmaceutical formulations includes:

• Most Favored Nation (MFN) Tariff Rates: Standardized rates applied to imports from all WTO member countries.

• Basic Customs Duty: A percentage of the product's value, subject to change based on government policies.

• Integrated Goods and Services Tax (IGST): Applied to imported goods, including pharmaceuticals, to integrate the tax system.

• Health Cess: An additional levy on imported medical products to fund health initiatives.

These tariffs are subject to periodic revisions and can impact the pricing and competitiveness of imported pharmaceutical products.

As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Algeria that offer preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations, but does not include specific provisions for pharmaceutical products between them. Bilateral negotiations may occur, but no significant agreements have been reported in the pharmaceutical sector.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and promotes access to affordable medicines. Compulsory licensing provisions allow the government to authorize the production of patented drugs without the consent of the patent holder under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability and accessibility for the Indian population.

Pharmaceutical shipments from Algeria to India are typically transported via sea routes, with major ports such as Algiers and Oran serving as export points. The transit time for sea freight from Algeria to India varies depending on the specific ports of departure and arrival, but generally ranges from 20 to 30 days. Air freight options are also available, offering faster delivery times but at higher costs. The reliability of these routes is generally high, with established shipping lines and logistics providers facilitating the movement of goods.

Algeria's key export ports include Algiers and Oran, which are equipped to handle pharmaceutical shipments. In India, major import ports such